Schedule 13G ownership disclosure

ArriVent BioPharma, Inc.

Common Stock, par value $0.0001 per share · CUSIP: 0472N1020

Event date: 2025-02-07

Filing-level shares
1,750,000
Percent of class
5.2%
  • Novo Holdings A/S

    Shares: 1,750,000 · Class: 5.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-021707
Form type
SCHEDULE 13G
Filer
ArriVent BioPharma, Inc.
CIK
CIK 1868279
Filed
Feb 14, 2025
Reporting period
Feb 07, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub